Seasonal epidemics and periodic worldwide pandemics caused by influenza A viruses are of continuous concern. The viral nonstructural (NS1) protein is a multifunctional virulence factor that antagonizes several host innate immune defenses during infection. NS1 also directly stimulates class IA phosphoinositide 3-kinase (PI3K) signaling, an essential cell survival pathway commonly mutated in human cancers. Here, we present a 2.3-Å resolution crystal structure of the NS1 effector domain in complex with the inter-SH2 (coiled-coil) domain of p85β, a regulatory subunit of PI3K. Our data emphasize the remarkable isoform specificity of this interaction, and provide insights into the mechanism by which NS1 activates the PI3K (p85β:p110) holoenzyme. A model of the NS1:PI3K heterotrimeric complex reveals that NS1 uses the coiled-coil as a structural tether to sterically prevent normal inhibitory contacts between the N-terminal SH2 domain of p85β and the p110 catalytic subunit. Furthermore, in this model, NS1 makes extensive contacts with the C2/kinase domains of p110, and a small acidic α-helix of NS1 sits adjacent to the highly basic activation loop of the enzyme. During infection, a recombinant influenza A virus expressing NS1 with charge-disruption mutations in this acidic α-helix is unable to stimulate the production of phosphatidylinositol 3,4,5-trisphosphate or the phosphorylation of Akt. Despite this, the charge-disruption mutations in NS1 do not affect its ability to interact with the p85β inter-SH2 domain in vitro. Overall, these data suggest that both direct binding of NS1 to p85β (resulting in repositioning of the N-terminal SH2 domain) and possible NS1:p110 contacts contribute to PI3K activation.C lass IA phosphoinositide 3-kinases (PI3Ks) are obligate heterodimeric enzymes consisting of a 110-kDa catalytic subunit (p110α, p110β, or p110δ) bound to a noncatalytic 85-kDa regulatory subunit (typically p85α or p85β) (1). Growth factor receptor-mediated activation of PI3K requires the relocalization of p85:p110 heterodimers to the plasma membrane, where disinhibition of p110 by p85 leads to the production of phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ). PIP 3 is an intracellular lipid second messenger that recruits pleckstrin homology domain-containing effectors (including protein kinases such as Akt) to the membrane. Subsequent activation of these effectors stimulates a plethora of signaling cascades that regulate diverse biological processes, including cell survival, proliferation, and metabolism (2). Given that PI3K is among the most frequently mutated enzymes associated with human cancers (3, 4), there is considerable interest in trying to understand the structural basis for both normal and pathophysiological regulation of p110 by p85 (5-7). Such studies are likely to yield insights into the novel mechanisms by which PI3K can be aberrantly activated, and may provide the focus for designing selective inhibitors targeting specific diseases.During infection, the PI3K signaling pathway is activated by influenz...